Gain Therapeutics Management
Management Kriterienprüfungen 2/4
Gain Therapeutics CEO ist Gene Mack , ernannt in Jun 2024, hat eine Amtszeit von 1.92 Jahren. Die jährliche Gesamtvergütung beträgt $1.47M , bestehend aus 34.1% Gehalt und 65.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.034% der Aktien des Unternehmens, im Wert von $25.63K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.2 Jahre bzw. 5.3 Jahre.
Wichtige Informationen
Gene Mack
Geschäftsführender
US$1.5m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 34.08% |
| Amtszeit als Geschäftsführer | 1.9yrs |
| Eigentum des Geschäftsführers | 0.03% |
| Durchschnittliche Amtszeit des Managements | 2.2yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 5.3yrs |
Jüngste Management Updates
Recent updates
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
Gain Therapeutics’ Parkinson’s candidate GT-02287 showed durable clinical stability and biomarker improvements in extended Phase 1b data.3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.3 US Biotechs Developing Parkinson’s Therapies
Global markets may be dealing with inflation, shifting rate expectations, and energy volatility, but companies tackling long-term health challenges like Parkinson’s disease are still pushing ahead.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients
Summary Gain Therapeutics achieved functional improvement in Parkinson’s patients with GT-02287 in its Phase 1b trial, notably improving MDS-UPDRS Part III motor scores. GT-02287’s mechanism addresses GCase misfolding earlier in the disease process, potentially offering superior efficacy versus competitors. GANX’s $66 million market cap is seen as deeply undervalued given positive trial data, large market potential, and higher-value biotech acquisitions. I reiterate a Strong Buy rating for GANX. Read the full article on Seeking AlphaGain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results
Summary Gain Therapeutics' GT-02287 shows promising efficacy and safety data, targeting both idiopathic and GBA1 Parkinson’s disease, with potential for substantial market impact and investor gains. The drug's ability to restore GCase function and its positive preclinical and Phase 1 results highlight its potential as a best-in-class treatment. Gain's aggressive development strategy and strong data sharing indicate confidence, with Phase 1b trial results expected by mid-2025, potentially increasing the company's valuation. Read the full article on Seeking AlphaGain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
Summary Gain Therapeutics, Inc.'s drug candidate GT-02287 has best-in-class potential to slow or stop disease progression in Parkinson's disease. Gain is progressing at an impressive speed through its Phase 1 trial. Drug discovery engine Magellan, which had already generated a Phase 3 drug in the past, may be overlooked by investors. Gain Therapeutics is considerably undervalued compared to peers and recent acquisition targets in the neurodegenerative space. Read the full article on Seeking AlphaGain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Summary Gain Therapeutics' drug candidate GT-02287 targets GCase and lysosomal dysfunction, potentially succeeding where others may fail. The company's AI-driven drug discovery engine has generated several targets across different diseases. GT-02287 is currently in a Phase 1 trial for GBA-1-PD, and Gain will add further preclinical data in February to its already interesting preclinical dataset. Gain's stock has been performing well, and similarities with a recent acquisition of Caraway Therapeutics by Merck may confirm its undervaluation. Read the full article on Seeking AlphaGain Therapeutics appoints CEO
Biotechnology company Gain Therapeutics (NASDAQ:GANX) said COO Matthias Alder has been appointed CEO, effective immediately. Alder, who was also appointed to the company's board, succeeds Eric Richman. The size of the company's board is now increased to eight members. Richman will continue to serve as a board member and as a senior advisor. Source: Press ReleaseGain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Gain Therapeutics has a market cap of just $84m. The biotech is developing small molecules to treat rare genetic diseases. The company uses a proprietary drug discovery engine, SEE-Tx, which targets allosteric binding sites, and misfolded proteins - approaches previously validated either by trial data or major investment. Gain has not yet had an IND accepted by the FDA, but targets include GM1 Gangliosidosis, Parkinson's, and Gaucher Disease. There are areas of high unmet need and competitive fields, but Gain does at least have some promising preclinical data. The $7 per share entry point feels cheap to me, with numerous upcoming catalysts, an experienced management team and Board, and oral availability all plus points.Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets. Public investors can access this disruptive technology at a venture-like valuation. A clean balance sheet funds the business until H2 2023, with multiple value inflections expected. Management has a track record of creating value through pharma partnerships and exits. Approaching top-line data for lead compound in GBA1 Parkinson’s has game-changing potential.Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$21m |
| Dec 31 2025 | US$1m | US$500k | -US$20m |
| Sep 30 2025 | n/a | n/a | -US$19m |
| Jun 30 2025 | n/a | n/a | -US$19m |
| Mar 31 2025 | n/a | n/a | -US$21m |
| Dec 31 2024 | US$991k | US$271k | -US$20m |
Vergütung im Vergleich zum Markt: GeneDie Gesamtvergütung ($USD1.47M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD624.15K).
Entschädigung vs. Einkommen: GeneDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Gene Mack (51 yo)
Mr. Gene Mack, M.B.A. is President, Chief Executive Officer & Director of Gain Therapeutics, Inc. from January 06, 2025 and was its Chief Financial Officer since April 8, 2024 until January 06, 2025 and wa...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman & Founder | 9.3yrs | US$93.15k | 2.18% $ 1.7m | |
| President | 1.9yrs | US$1.47m | 0.034% $ 25.6k | |
| Senior VP of Finance & Principal Financial Officer | 1.3yrs | US$345.07k | 0.079% $ 59.7k | |
| Senior Vice President of Technical Operations | no data | keine Daten | keine Daten | |
| Senior Vice President of Research | 3.9yrs | keine Daten | keine Daten | |
| Chief Medical Officer | 2.2yrs | keine Daten | keine Daten |
Erfahrenes Management: GANXDas Führungsteam des Unternehmens gilt als erfahren (2.2 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman & Founder | 9.3yrs | US$93.15k | 2.18% $ 1.7m | |
| President | 1.3yrs | US$1.47m | 0.034% $ 25.6k | |
| Independent Director | 5.3yrs | US$80.15k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | keine Daten | keine Daten | |
| Independent Director | 5.3yrs | US$63.15k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$76.65k | 0% $ 0 | |
| Independent Director | 7yrs | US$78.65k | 0.070% $ 53.4k | |
| Independent Director | 5.3yrs | US$68.15k | 0% $ 0 | |
| Member of Clinical Advisory Board | 1.3yrs | keine Daten | keine Daten | |
| Member of Clinical Advisory Board | 1.3yrs | keine Daten | keine Daten | |
| Member of Clinical Advisory Board | 1.3yrs | keine Daten | keine Daten |
Erfahrener Vorstand: GANXDie Vorstandsmitglieder gelten als erfahren (5.3 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/26 12:40 |
| Aktienkurs zum Tagesende | 2026/05/26 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Gain Therapeutics, Inc. wird von 7 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Raghuram Selvaraju | H.C. Wainwright & Co. |